CME: NSCLC Case by Case: Optimizing 1L Immunotherapy for Advanced & Metastatic Disease Medical Education on ReachMD

Overview
The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the last few years. This program aims to improve the understanding among oncology clinicians of the application and use of IO to treat patients with advanced or metastatic NSCLC without actionable driver alterations, including guideline recommendations for the duration of therapy and how best to manage special populations, while optimizing care by minimizing immune-related adverse events.
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, including Oncologists, Nurses, Pharmacists and Advanced Care Practitioners involved in the management of patients with advanced/metastatic NSCLC.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Select optimal frontline treatment strategies for patients with advanced non-small cell lung cancer without actionable driver alterations by incorporating treatment-specific and patient-related characteristics
- Implement evidence-based strategies to monitor and mitigate immune-related adverse events to optimize treatment adherence and patient outcomes
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Faculty Disclosure of Commercial Relationships
Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

The following faculty have disclosed:

Joshua E. Reuss, MD, faculty for this educational event, receives research funds from Genentech/Roche, Nuvalent, and Verastem; and receives consulting fees from Genentech/Roche, Sanofi/Genzyme, Personalis, Guardant, Astrazeneca, BMS, Arcus, Abbvie, and Merck.

Charu Aggarwal, MD, MPH, faculty for this educational event, receieves research funds from Genentech/Roche, Incyte, Macrogenic, Merck Sharp &Dohme, AstraZencea/ Medimmune; and receives consulting fees from Genentech, Lily, Celgene, Merck, Astra Zencea, Blueprint Genetics, Shionogi, Daiichi Sankyo/AstraZencea, Regeneron/ Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, Boehringer Ingelheim.
Planners and Managers Disclosure List
The following planners/reviewers/managers have disclosed:

Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Acknowledgment
This activity is supported by independent educational grants from Bristol Myers Squibb and Regeneron Pharmaceuticals, Inc.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Fee Statement
This activity is FREE to all participants.
Instructions for Completion
During the period 7/14/2023 through 7/14/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 07/14/2023
Expiration Date: 07/14/2024